BioCryst Pharmaceuticals
BCRX
BCRX
234 hedge funds and large institutions have $1.87B invested in BioCryst Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 76 increasing their positions, 59 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
234
Holders Change
+13
Holders Change %
+5.88%
% of All Funds
4.05%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
42
Increased
76
Reduced
59
Closed
26
Calls
$54.3M
Puts
$18M
Net Calls
+$36.2M
Net Calls Change
+$11.7M
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
$114M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
$17.9M |
| 3 |
Two Sigma Investments
New York
|
$13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
$71.9M |
| 5 |
D.E. Shaw & Co
New York
|
$6.24M |
